CREBZF: A Potential Drug Target for Neurological Disorders (G58487)

Target Name: CREBZF

NCBI ID: G58487

CREBZF

CREBZF: A Potential Drug Target for Neurological Disorders

CREBZF, also known as HCF-binding transcription factor, is a protein that plays a crucial role in the regulation of gene expression in the brain. It is a transcription factor that is highly expressed in the brain and is known to play a key role in the development and progression of various neurological disorders, including Alzheimer's disease.

CREBZF is a member of the CREB/CBP gene family, which is known for its role in the regulation of gene expression and the control of cell cycle progression. The CREB/CBP gene family is composed of several transcription factors, including CREB, CBP, and p16, which are highly expressed in the brain and are known to play a key role in the regulation of gene expression.

CREBZF is a protein that is highly expressed in the brain and is known to play a crucial role in the regulation of gene expression in the brain. It is a transcription factor that is highly expressed in the brain and is known to play a key role in the development and progression of various neurological disorders, including Alzheimer's disease.

One of the most significant functions of CREBZF is its ability to bind to the protein HCF, which is a transcription factor that is highly expressed in the brain and is known to play a key role in the regulation of gene expression. The CREB/HCF interaction is critical for the regulation of gene expression and is a key factor in the development and progression of various neurological disorders.

CREBZF has been shown to play a key role in the regulation of gene expression in the brain and is a potential drug target for the treatment of various neurological disorders. For example, studies have shown that CREBZF is highly expressed in the brain and is associated with the development of Alzheimer's disease. Additionally, experiments have shown that inhibition of CREBZF has been shown to protect against the development of neurodegeneration in various models of disease, including Alzheimer's disease.

In addition to its role in the regulation of gene expression, CREBZF is also known to play a key role in the regulation of cellular processes, including cell cycle progression and apoptosis. Studies have shown that CREBZF is involved in the regulation of the G1/S transition, which is a critical step in the cell cycle and is associated with the G1 phase of the cell cycle. Additionally, experiments have shown that CREBZF is involved in the regulation of apoptosis, which is a natural process that is involved in the elimination of damaged cells and is a key factor in the regulation of cell survival.

In conclusion, CREBZF is a protein that is highly expressed in the brain and is known to play a crucial role in the regulation of gene expression in the brain. Its role in the regulation of gene expression and cellular processes, including cell cycle progression and apoptosis , makes it a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease. Further research is needed to fully understand the role of CREBZF in the regulation of gene expression and to develop effective treatments for neurological disorders.

Protein Name: CREB/ATF BZIP Transcription Factor

Functions: Strongly activates transcription when bound to HCFC1. Suppresses the expression of HSV proteins in cells infected with the virus in a HCFC1-dependent manner. Also suppresses the HCFC1-dependent transcriptional activation by CREB3 and reduces the amount of CREB3 in the cell. Able to down-regulate expression of some cellular genes in CREBZF-expressing cells

The "CREBZF Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CREBZF comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets